Elevation Oncology, Inc. Profile Avatar - Palmy Investing

Elevation Oncology, Inc.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-…

Biotechnology
US, New York [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of ELEV's Analysis
CIK: 1783032 CUSIP: 28623U101 ISIN: US28623U1016 LEI: - UEI: -
Secondary Listings
ELEV has no secondary listings inside our databases.